Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug development: target practice.

× No keyword cloud information.

5 in total

1. New designs for phase 2 clinical trials.

Authors: Elihu H Estey; Peter F Thall
Journal: Blood Date: 2003-01-30 Impact factor: 22.113

2. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors: Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal: Sci Transl Med Date: 2011-08-10 Impact factor: 17.956

3. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

Authors: Aniruddha J Deshpande; Liying Chen; Maurizio Fazio; Amit U Sinha; Kathrin M Bernt; Deepti Banka; Stuart Dias; Jenny Chang; Edward J Olhava; Scott R Daigle; Victoria M Richon; Roy M Pollock; Scott A Armstrong
Journal: Blood Date: 2013-01-29 Impact factor: 22.113

4. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Authors: Jeffrey W Tyner; Wayne F Yang; Armand Bankhead; Guang Fan; Luke B Fletcher; Jade Bryant; Jason M Glover; Bill H Chang; Stephen E Spurgeon; William H Fleming; Tibor Kovacsovics; Jason R Gotlib; Stephen T Oh; Michael W Deininger; Christian Michel Zwaan; Monique L Den Boer; Marry M van den Heuvel-Eibrink; Thomas O'Hare; Brian J Druker; Marc M Loriaux
Journal: Cancer Res Date: 2012-10-18 Impact factor: 12.701

5. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Authors: Renier J Brentjens; Marco L Davila; Isabelle Riviere; Jae Park; Xiuyan Wang; Lindsay G Cowell; Shirley Bartido; Jolanta Stefanski; Clare Taylor; Malgorzata Olszewska; Oriana Borquez-Ojeda; Jinrong Qu; Teresa Wasielewska; Qing He; Yvette Bernal; Ivelise V Rijo; Cyrus Hedvat; Rachel Kobos; Kevin Curran; Peter Steinherz; Joseph Jurcic; Todd Rosenblat; Peter Maslak; Mark Frattini; Michel Sadelain
Journal: Sci Transl Med Date: 2013-03-20 Impact factor: 17.956

5 in total

3 in total

Drug development: target practice.

1. New designs for phase 2 clinical trials.

2. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

3. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

4. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

5. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Review 1. Overcoming cancer therapeutic bottleneck by drug repurposing.

2. Targeted nanotherapeutics in cancer.

Review 3. Progress and prospects for engineered T cell therapies.